Address: 9, chemin des Mines
Case postale 54
CH-1211 Geneva,Germany
Tel: +41-22-414 3000
Web: http://www.merckserono.com/en/index.html
Merck Serono is the division for innovative small molecules and biopharmaceuticals of Merck KGaA. Merck Serono’s global headquarters are located in Geneva, Switzerland. In the United States and Canada, the division operates
as EMD Serono
Merck Serono combines its complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) to offer innovative prescription drugs of either origin.
With comprehensive skills in all areas from research and development to manufacturing, marketing and sales, the division offers its world-class products in over 150 countries worldwide. Our strategically positioned workforce of 8,000 sales and marketing employees ensures commercial coverage in the U.S. and Canada, Latin America, Europe, Asia-Pacific and Japan
Oncology
Neurodegenerative diseases
Fertility
Endocrinology
Cardiometabolic care
The country manager of a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials describes the initiatives she has been putting in place to optimise…
Deborah Brown, President of EMD Serono Canada, talks about Canada’s emerging market mentality, despite being a developed country, and how this lack of innovation and risk-taking could ultimately break Canada’s…
Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the…
Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the…
Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’…
At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is…
Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer…
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe. More…
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the…
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the…
A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country,…
See our Cookie Privacy Policy Here
